{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:18:53Z","timestamp":1788185933094,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12185-026-04222-1","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:13:59Z","timestamp":1778555639000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized multivariable clinical prognostic model for patients with acute myeloid leukemia receiving intensive chemotherapy"],"prefix":"10.1007","volume":"124","author":[{"given":"Kengo","family":"Katsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-4757","authenticated-orcid":false,"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moka","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"4222_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. version 1; 2025- December 20, 2024"},{"key":"4222_CR2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017. Cancer. 2021;127:2049\u201361.","journal-title":"Cancer"},{"key":"4222_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"4222_CR4","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"4222_CR5","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network; TJ Ley C Miller L Ding BJ Raphael AJ Mungall et al 2013 Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 368 2059 2074","DOI":"10.1056\/NEJMoa1301689"},{"key":"4222_CR6","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"4222_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"4222_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ng.3756","volume":"49","author":"M Gerstung","year":"2017","unstructured":"Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49:332\u201340.","journal-title":"Nat Genet"},{"key":"4222_CR9","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","volume":"3","author":"ML Sorror","year":"2017","unstructured":"Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, et al. Development and validation of a novel acute myeloid leukemia\u2013composite model to estimate risks of mortality. JAMA Oncol. 2017;3:1675\u201382.","journal-title":"JAMA Oncol"},{"key":"4222_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ajh.26557","volume":"97","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, et al. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022;97:865\u201376.","journal-title":"Am J Hematol"},{"key":"4222_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364\u201370.","journal-title":"J Clin Oncol"},{"key":"4222_CR12","first-page":"380","volume":"5","author":"LT Madsen","year":"2014","unstructured":"Madsen LT. Cancer prediction nomograms for advanced practitioners in oncology. J Adv Pract Oncol. 2014;5:380\u20132.","journal-title":"J Adv Pract Oncol"},{"key":"4222_CR13","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117:2366\u201372.","journal-title":"Blood"},{"key":"4222_CR14","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117:2358\u201365.","journal-title":"Blood"},{"key":"4222_CR15","doi-asserted-by":"crossref","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. 1998 The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children\u2019s Leukaemia Working Parties. Blood. 92 2322 2333","DOI":"10.1182\/blood.V92.7.2322.2322_2322_2333"},{"key":"4222_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bjh.12750","volume":"165","author":"R Liersch","year":"2014","unstructured":"Liersch R, M\u00fcller-Tidow CM, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adults\u2014biological significance and clinical use. Br J Haematol. 2014;165:17\u201338.","journal-title":"Br J Haematol"},{"key":"4222_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.18381","volume":"199","author":"A Alsouqi","year":"2022","unstructured":"Alsouqi A, Rothenberger SD, Boyiadzis M, Lontos K. Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: an analysis of 55\u2009985 patients from the National Cancer Database. Br J Haematol. 2022;199:256\u20139.","journal-title":"Br J Haematol"},{"key":"4222_CR18","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417\u201323.","journal-title":"J Clin Oncol"},{"key":"4222_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clml.2018.03.009","volume":"18","author":"T Tachibana","year":"2018","unstructured":"Tachibana T, Andou T, Tanaka M, Ito S, Miyazaki T, Ishii Y, et al. Clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia: a YACHT multicenter retrospective study. Clin Lymphoma Myeloma Leuk. 2018;18:415\u201321.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4222_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12185-017-2183-7","volume":"105","author":"T Ando","year":"2017","unstructured":"Ando T, Yamazaki E, Ogusa E, Ishii Y, Yamamoto W, Motohashi K, et al. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. Int J Hematol. 2017;105:623\u201330.","journal-title":"Int J Hematol"},{"key":"4222_CR21","doi-asserted-by":"publisher","first-page":"e3228","DOI":"10.1002\/hon.3228","volume":"42","author":"T Sakuma","year":"2024","unstructured":"Sakuma T, Fujisawa S, Tanaka M, Hagihara M, Fujita H, Fujimaki K, et al. Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: a multicenter retrospective study. Hematol Oncol. 2024;42:e3228.","journal-title":"Hematol Oncol"},{"key":"4222_CR22","first-page":"3947","volume":"33","author":"T Yamauchi","year":"2013","unstructured":"Yamauchi T, Negoro E, Lee S, Takai M, Matsuda Y, Takagi K, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013;33:3947\u201351.","journal-title":"Anticancer Res"},{"key":"4222_CR23","doi-asserted-by":"publisher","first-page":"e00189","DOI":"10.1097\/BS9.0000000000000189","volume":"6","author":"J Chen","year":"2024","unstructured":"Chen J, Hui Y, Zhai Y, Yang M, Zhang X, Mi Y, et al. Serum albumin is associated with the inherent property of acute myeloid leukemia and correlates with patient outcomes. Blood Sci. 2024;6:e00189.","journal-title":"Blood Sci"},{"key":"4222_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5603\/AHP.a2023.0022","volume":"54","author":"P Strza\u0142ka","year":"2023","unstructured":"Strza\u0142ka P, Czemerska M, Krawiec KM, Szyd\u0142owska S, Mikulski D, Pluta A, et al. Characterization and prognostic factors of secondary to MDS\/MPN and therapy-related AML: a single-center study. Acta Haematol Pol. 2023;54:176\u201386.","journal-title":"Acta Haematol Pol"},{"key":"4222_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12185-023-03677-w","volume":"119","author":"K Usuki","year":"2024","unstructured":"Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, et al. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). Int J Hematol. 2024;119:24\u201338.","journal-title":"Int J Hematol"},{"key":"4222_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41375-022-01745-4","volume":"37","author":"G Paras","year":"2023","unstructured":"Paras G, Othus M, Schonhoff K, Shaw C, Sorror M, Halpern AB, et al. Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia. 2023;37:231\u20134.","journal-title":"Leukemia"},{"key":"4222_CR27","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.20.01392","volume":"38","author":"R Palmieri","year":"2020","unstructured":"Palmieri R, Othus M, Halpern AB, Percival MM, Godwin CD, Becker PS, et al. Accuracy of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm. J Clin Oncol. 2020;38:4163\u201374.","journal-title":"J Clin Oncol"},{"key":"4222_CR28","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s00520-018-4582-6","volume":"27","author":"P Kuhlman","year":"2019","unstructured":"Kuhlman P, Isom S, Pardee TS, Burns C, Tawfik B, Lamar ZS, et al. Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. Support Care Cancer. 2019;27:2877\u201384.","journal-title":"Support Care Cancer"},{"key":"4222_CR29","doi-asserted-by":"publisher","first-page":"71526","DOI":"10.18632\/oncotarget.12245","volume":"7","author":"Z Zheng","year":"2016","unstructured":"Zheng Z, Li X, Zhu Y, Gu W, Xie X, Jiang J. Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia. Oncotarget. 2016;7:71526\u201335.","journal-title":"Oncotarget"},{"key":"4222_CR30","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.21037\/tcr-23-1192","volume":"12","author":"Y Guo","year":"2023","unstructured":"Guo Y, Niu Y, Liang H, Yang X, Jian J, Tang X, et al. A nomogram based on clinical features and molecular abnormalities for predicting the prognosis of patients with acute myeloid leukemia. Transl Cancer Res. 2023;12:3432\u201342.","journal-title":"Transl Cancer Res"},{"key":"4222_CR31","doi-asserted-by":"publisher","first-page":"103126","DOI":"10.1016\/j.ebiom.2020.103126","volume":"62","author":"TT Ma","year":"2020","unstructured":"Ma TT, Lin XJ, Cheng WY, Xue Q, Wang SY, Liu FJ, et al. Development and validation of a prognostic model for adult patients with acute myeloid leukaemia. EBioMedicine. 2020;62:103126.","journal-title":"EBioMedicine"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04222-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04222-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04222-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:23Z","timestamp":1788184583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04222-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4222"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04222-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shin Fujisawa reports honoraria from Bristol-Myers-Squibb, Nippon Shinyaku, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Novartis Pharma KK, Janssen, Kyowa Kirin Co., Ltd., AstraZeneca, CSL Behring KK, Meiji Seika Pharma, AbbVie Inc, Takeda Pharmaceutical Co., Ltd., Asahi Kasei Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Kissei, PharmaEssentia Japan, Genmab, Argenx Japan, Alexion Pharma, Inc., and Chugai Pharmaceutical Co., Ltd. and research funding from Shionogi Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Asahi-Kasei Pharma, and Daiichi Sankyo Co., Ltd., outside the submitted work. Takayoshi Tachibana reports honoraria from Nippon-Shinyaku, AbbVie, Astellas, MEIJI SEIKA pharma, Amgen, Chugai, Otsuka, Pfizer, Asahikasei-pharma, MSD, Daiichi Sankyo and Novartis, outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}